Novo Nordisk (NOV) Price & Analysis

Compare

523 Followers

NOV Stock Chart & Stats

€45.93

€0.79(0.95%)

At close: Jan 09 4:00 PM EST

€45.93

€0.79(0.95%)

Day’s Range― - ―

52-Week Range€38.54 - €108.82

Previous CloseN/A

Volume21.06K

Average Volume (3M)333.55K

Market Cap

kr203.25B

Enterprise Value€2.04T

Total Cash (Recent Filing)kr41.55B

Total Debt (Recent Filing)kr118.72B

Price to Earnings (P/E)13.7

Beta0.77

Next Earnings

Nov 05, 2025

EPS Estimate

0.67

Last Dividend Ex-Date

Aug 15, 2025

Dividend Yield3.35%

Share Statistics

EPS (TTM)0.80

Shares Outstanding3,390,128,000

10 Day Avg. Volume247,790

30 Day Avg. Volume333,550

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

kr58.85

Price Target Upside28.14% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering13

Bulls Say, Bears Say

Bulls Say

Clinical TrialsNovo Nordisk's trial for Rybelsus in Alzheimer's could be clinically meaningful even with modest benefits, thanks to its broad safety profile.

Product MixMore visibility on product mix with positive impact related to 340B, mostly from Ozempic with remainder being insulin, which explains NovoRapid and Tresiba beats.

Regulatory ProgressNovo Nordisk confirmed the filing of the Semaglutide 7.2mg dose in the US, indicating regulatory progress.

Bears Say

Growth ConcernsThe company is not viewed as a 'premium' growth entity anymore, with debates expected around the trading price-to-earnings multiple into the future.

Prescription TrendsThere is a lack of growth in prescription trends for Wegovy and Ozempic, with market pressure anticipated from patent expiry and competitor launches.

Sales GuidanceThere is a risk of a top-end sales guide cut for FY25, with implications continuing into FY26, due to disappointing sales trajectories.

Novo Nordisk News

Novo Nordisk assumed with an Underperform at Jefferies

Jefferies assumed coverage of Novo Nordisk (NVO) with an Underperform rating and DKK 290 price target Obesity growth...

1h ago

NVO

Novo Nordisk backed MapLight raises $258.9M in IPO, Bloomberg says

Novo Nordisk (NVO) backed MapLight Therapeutics will raise $258.9M in an IPO and private placement, Avalon Pernell of...

12h ago

NVO

Mixed options sentiment in Novo Nordisk with shares down 0.59%

Mixed options sentiment in Novo Nordisk (NVO), with shares down 32c near $53.06. Options volume relatively light with...

4d ago

NVO

Midday Fly By: Netflix, TI reports weigh on markets

Stocks were lower in morning trading as investors navigated a busy earnings season, with Netflix’s weaker-than-expected profit weighing...

5d ago

Mixed options sentiment in Novo Nordisk with shares down 2.58%

Mixed options sentiment in Novo Nordisk (NVO), with shares down $1.42 near $53.37. Options volume roughly in line...

5d ago

NVO

Trump Trade: Trump administration prepares new probe into pharma prices

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by...

5d ago

AZN

Trump admin prepares new probe into U.S. pharma prices, FT says

President Donald Trump’s administration is preparing a new probe into U.S. trading partners over drug pricing, Aime Williams...

5d ago

AZN

Novo Nordisk to sharpen focus on U.S. consumers, Reuters reports

Novo Nordisk’s (NVO) largest shareholder is taking control of the drugmaker’s board, with plans to revive sales growth...

5d ago

NVO

Mixed options sentiment in Novo Nordisk with shares down 1.44%

Mixed options sentiment in Novo Nordisk (NVO), with shares down 80c near $54.94. Options volume relatively light with...

6d ago

NVO

Midday Fly By: GM, Coca-Cola report Q3 beats

The major averages were mixed near noon as the U.S. government shutdown approaches its fourth week. The Dow...

6d ago

Cautious Hold Rating on Novo Nordisk Amid Competitive Pressures and Uncertain Growth Prospects

Analyst Evan Seigerman of BMO Capital reiterated a Hold rating on Novo Nordisk, boosting the price target to...

13d ago

NVO

Cautious Outlook for Novo Nordisk Amid Uncertain Pipeline Outcomes and Growth Challenges

Analyst Sachin Jain of Bank of America Securities maintained a Hold rating on Novo Nordisk, with a price...

1M ago

NVO

Hold Rating for Novo Nordisk Amid Restructuring and Market Challenges

Analyst Sachin Jain of Bank of America Securities maintained a Hold rating on Novo Nordisk, with a price...

2M ago

NVO

Novo Nordisk’s Strategic Restructuring Faces Uncertainty Amid Competitive Pressures

In a report released today, Evan Seigerman from BMO Capital maintained a Hold rating on Novo Nordisk, with...

2M ago

NVO

NOV FAQ

What was Novo Nordisk’s price range in the past 12 months?

Novo Nordisk lowest stock price was €38.54 and its highest was €108.82 in the past 12 months.

What is Novo Nordisk’s market cap?

Novo Nordisk’s market cap is kr203.25B.

When is Novo Nordisk’s upcoming earnings report date?

Novo Nordisk’s upcoming earnings report date is Nov 05, 2025 which is in 9 days.

How were Novo Nordisk’s earnings last quarter?

Novo Nordisk released its earnings results on Aug 06, 2025. The company reported €0.798 earnings per share for the quarter, beating the consensus estimate of €0.794 by €0.004.

Is Novo Nordisk overvalued?

According to Wall Street analysts Novo Nordisk’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Novo Nordisk pay dividends?

Novo Nordisk pays a Semiannually dividend of €0.502 which represents an annual dividend yield of 3.35%. See more information on Novo Nordisk dividends here

What is Novo Nordisk’s EPS estimate?

Novo Nordisk’s EPS estimate is 0.67.

How many shares outstanding does Novo Nordisk have?

Novo Nordisk has 3,390,128,000 shares outstanding.

What happened to Novo Nordisk’s price movement after its last earnings report?

Novo Nordisk reported an EPS of €0.798 in its last earnings report, beating expectations of €0.794. Following the earnings report the stock price went down -4.577%.

Which hedge fund is a major shareholder of Novo Nordisk?

Currently, no hedge funds are holding shares in DE:NOV

Company Description

Novo Nordisk

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novo Nordisk (NOV) Earnings & Revenues

Historic Earnings Reports

NOV Stock 12 Month Forecast

Average Price Target

€58.85

▲(28.14% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"40":"€40","56":"€56","72":"€72","88":"€88","104":"€104"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":80.3022,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€80.30</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":58.85482075,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€58.85</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45.50458,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€45.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[40,56,72,88,104],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50.07,52.395553846153845,54.72110769230769,57.046661538461535,59.37221538461539,61.697769230769225,64.02332307692308,66.34887692307692,68.67443076923077,70.99998461538462,73.32553846153846,75.65109230769231,77.97664615384615,{"y":80.3022,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50.07,50.74575544230769,51.42151088461539,52.09726632692308,52.77302176923077,53.44877721153846,54.12453265384615,54.80028809615385,55.47604353846154,56.15179898076923,56.827554423076926,57.503309865384615,58.17906530769231,{"y":58.85482075,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50.07,49.71881384615384,49.36762769230769,49.016441538461535,48.665255384615385,48.31406923076923,47.96288307692308,47.61169692307692,47.26051076923077,46.90932461538461,46.55813846153846,46.206952307692305,45.85576615384615,{"y":45.50458,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":103.754,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.351,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.837,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.418,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.367,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.034,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.389,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.666,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.667,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.842,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.168,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.92,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.07,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >